NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Lyell Immunopharma, Inc. (LYEL) Stock Analysis

Lyell Immunopharma, Inc. (LYEL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

LYEL

$9.41

−$0.29 (−2.99%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LYEL with… →

LYEL Key Statistics

As of Oct 21, 2026
Trading
Open
$9.65
Previous Close
$9.70
Day's Range
9.29–10.12
52-Week Range
7.20–45.00
Volume
118.32K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.03
Valuation
Market Cap
$230.59M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
8,540.50
EPS (ttm)Profit attributable to each share over the last twelve months.
−12.86
Financials (FY)
Revenue (FY)
$36.00K−40.98%
Net Income (FY)
−$274.45M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
24.51M
1-Year Return
−45.67%
Dividend and dates
Earnings Date
November 6, 2026estimated
Avg Volume
154.09K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, LYEL closed at $9.41, −45.67% over 1 year.

Lyell Immunopharma, Inc. (LYEL) has a market capitalization of $230.59M.

In fiscal 2025, LYEL reported revenue of $36.00K.

LYEL Stock Return by Calendar Year

Lyell Immunopharma, Inc. (LYEL) return since Jun 2021: what $10,000 became

1 year
$10,000 $5,433
−45.67%
5 years
$10,000 $339
−96.61%
Since Jun 2021
$10,000 $279
−97.21%

If you had invested $10,000 in Lyell Immunopharma, Inc. (LYEL) at the close on June 17, 2021, the earliest close on record here, it would have been worth $279 at the close on October 21, 2026: −97.21% in total, −48.83% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−69.43%
2025+140.47%
2024−67.01%
2023−44.09%
2022−55.17%
2021 (partial year)−54.17%

As of October 21, 2026.

LYEL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$36.00K−$274.45M−762,355.6%
2024$61.00K−$342.99M−562,285.2%
2023$130.00K−$234.63M−180,486.2%
2022$84.68M−$183.12M−216.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$36.00K—−$201.63M−$274.45M−762,355.6%
2024$61.00K—−$220.27M−$342.99M−562,285.2%
2023$130.00K—−$247.01M−$234.63M−180,486.2%
2022$84.68M—−$187.06M−$183.12M−216.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Lyell Immunopharma, Inc. (LYEL) at $230.59M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 161.

Over the past 52 weeks the price has ranged from $7.20 to $45.00. The most recent close on file for LYEL is $9.41, dated October 21, 2026. That is −$0.29 (−2.99%) against the previous close. The latest close sits 30.79% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $36.00K. Against the prior fiscal year total of $61.00K, that is a change of −40.98%. The same year closed with a net loss of $274.45M. Earnings per share on a trailing basis come to −12.86.

Across the 4 fiscal years on file, revenue moves from $84.68M in 2022 to $36.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 8,540.5. On price-to-sales that is 642.2 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is −0.03. Daily returns over the trailing 5 years annualize to a volatility of 94.67%. The trailing one-year total return is −45.67%. Across 5 years the annualized return works out at −49.19%.

Growth & Income

No dividend is on file for LYEL.

The strongest complete calendar year on file is 2025 at +140.47%; the weakest is 2024 at −67.01%. Of the 4 complete calendar years on file, 1 finished higher. 2026 is still running; the total return is −69.43% year to date.

Peer Comparison

Lyell Immunopharma, Inc. (LYEL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Lyell Immunopharma, Inc. LYEL $230.59M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Lyell Immunopharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Visit website →